EUVIMEDEUVIMED entdecken
Crossref

Dual Nicotinamide Phosphoribosyltransferase (NAMPT) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors for the Treatment of Drug-Resistant Nonsmall-Cell Lung Cancer

Kaizhen Wang, Ke Ye, Xiangyu Zhang, Tianyu Wang, Zhihao Qi, Youjun Wang, Sheng Jiang iD, Kuojun Zhang

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.2c01954 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Kaizhen Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009,…. Hauptthemen laut MEDLINE: Nicotinamide Phosphoribosyltransferase, Lung Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China, Postdoctoral Research Program of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Depleting NAD+ by blocking its biosynthesis has emerged as an attractive anticancer strategy. Simultaneous blockade of NAD+ production from the salvage and de novo synthesis pathways by targeting NAMPT and IDO1 could achieve more effective NAD+ reduction and, subsequently, more robust antitumor efficacy. Herein, we report the discovery of the first series of dual NAMPT and IDO1 inhibitors according to multitarget drug rationales. Compound 10e has good and balanced inhibitory potencies against NAMPT and IDO1, and significantly inhibits both proliferation and migration of a NSCLC cell line resistant to taxol and FK866 (A549/R cells). Compound 10e also displays potent antitumor efficacy in A549/R xenograft mouse models with no significant toxicity. Moreover, this compound enhances the susceptibility of A549/R cells to taxol in vitro and in vivo. This work provides an efficient approach to targeting NAD+ metabolism in the area of cancer therapy, especially in the context of drug resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nicotinamide PhosphoribosyltransferaseLung NeoplasmsHumansAnimalsMiceIndoleamine-Pyrrole 2,3,-DioxygenaseNADCell Line, TumorCytokinesPaclitaxel

Substanzen

Nicotinamide PhosphoribosyltransferaseIndoleamine-Pyrrole 2,3,-DioxygenaseNADCytokinesPaclitaxel

Autor:innen und Institutionen

  • State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.

ORCID-Profile: Sheng Jiang

Förderung

  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China
  • Postdoctoral Research Program of Jiangsu Province

Zitieren

APA

Wang, K., Ye, K., Zhang, X., Wang, T., Qi, Z., Wang, Y., Jiang, S., & Zhang, K. (2023). Dual Nicotinamide Phosphoribosyltransferase (NAMPT) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors for the Treatment of Drug-Resistant Nonsmall-Cell Lung Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c01954

Vancouver

Wang K, Ye K, Zhang X, Wang T, Qi Z, Wang Y, et al. Dual Nicotinamide Phosphoribosyltransferase (NAMPT) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors for the Treatment of Drug-Resistant Nonsmall-Cell Lung Cancer. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.2c01954

BibTeX
@article{Wang2023,
  author = {Wang, Kaizhen and Ye, Ke and Zhang, Xiangyu and Wang, Tianyu and Qi, Zhihao and Wang, Youjun and Jiang, Sheng and Zhang, Kuojun},
  title = {Dual Nicotinamide Phosphoribosyltransferase (NAMPT) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors for the Treatment of Drug-Resistant Nonsmall-Cell Lung Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.2c01954}
}
Kostenlos starten →